Abstract
Triple therapy with telaprevir or boceprevir has proven to be effective in the treatment of chronic hepatitis C with response rates of up to 88%. However, the treatment may be associated with important adverse effects and a high economic impact. To assess the cost-effectiveness and safety of triple therapy with telaprevir or boceprevir for the treatment of chronic hepatitis C. Retrospective observational study. We included all patients who had started treatment with protease inhibitors before July 31(st), 2013. We evaluated sustained virological response, the cost per patient achieving sustained virological response, and the cost of the supportive treatment for adverse events associated with triple therapy. Fifty-nine patients were included; 35 had been treated with telaprevir (59.3%) and 24 with boceprevir (40.7%). Sustained virological response was achieved by 38 (64.4%) patients: 24 (68.6%) patients in the telaprevir treatment arm and 14 (58.3%) patients in the boceprevir treatment arm. The cost per patient with sustained virological response was 43,555 € (95% CI 35,389-51,722 €). There were no statistically significant differences between the overall costs of therapy with telaprevir, 43,494 € (95% CI 34,795 €-55,092 €) vers...Continue Reading
References
Nov 21, 2007·Journal of Hepatology·Juan I EstebanJosep Quer
Jun 12, 2010·Journal of Hepatology·Ava John-BaptisteGeorge Tomlinson
Jul 6, 2010·AIDS·Thijs J W van de LaarMark Danta
Nov 26, 2010·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D Lavanchy
Apr 1, 2011·The New England Journal of Medicine·Fred PoordadUNKNOWN SPRINT-2 Investigators
Jun 24, 2011·The New England Journal of Medicine·Ira M JacobsonUNKNOWN ADVANCE Study Team
Jun 24, 2011·The New England Journal of Medicine·Stefan ZeuzemUNKNOWN REALIZE Study Team
Sep 16, 2011·The New England Journal of Medicine·Kenneth E ShermanUNKNOWN ILLUMINATE Study Team
Nov 28, 2012·Journal of Hepatology·Savino BrunoMargaret H Burroughs
May 28, 2013·Journal of Hepatology·Calogero CammàUNKNOWN WEF Study Group
Jul 23, 2013·Journal of Hepatology·Manuel Romero-GómezJosé Luis Calleja
Aug 9, 2013·Gastroenterology·Fred PoordadUNKNOWN Protocol 6086 Investigators
Sep 4, 2013·PharmacoEconomics·Antonio Blázquez-PérezJavier Mar
Oct 12, 2013·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Donald B SmithPeter Simmonds
Nov 12, 2013·Alimentary Pharmacology & Therapeutics·L I BackusL A Mole
Mar 29, 2014·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Liesl M HaganRaymond F Schinazi
Apr 8, 2014·Gastroenterology·Christophe HézodeUNKNOWN CUPIC Study Group
Citations
Feb 19, 2017·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Timothy A Bach, Kathy Zaiken
Feb 16, 2020·International Journal of Environmental Research and Public Health·Elizabeth Parody-RúaIgnacio Aznar-Lou
Apr 17, 2020·European Journal of Hospital Pharmacy. Science and Practice·Luis Margusino-FramiñánÁngeles Castro-Iglesias
Oct 2, 2016·Clinical Liver Disease·Omar Y MousaVictor Ankoma-Sey